EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Baseline PSMA PET/CT parameters predict overall survival and treatment response in metastatic castration-resistant prostate cancer patients

Fleur Kleiburg, Lioe-Fee de Geus-Oei, Romy Spijkerman, Wyanne A Noortman, Floris H P van Velden, Srirang Manohar, Frits Smit, Frank A J Toonen, Saskia A C Luelmo, Tom van der Hulle, Linda Heijmen

European Radiology · 22.01.2025 · 35 (7) · 4223-4232

DOI: 10.1007/s00330-025-11360-3 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Radiology, online erschienen am 22.01.2025. Verfasst von Fleur Kleiburg und 10 weiteren Autor:innen. Beteiligte Einrichtung: Biomedical Photonic Imaging Group, University of Twente, Enschede, The Netherlands. F.Kleiburg@lumc.nl. Hauptthemen laut MEDLINE: Positron Emission Tomography Computed Tomography, Prostatic Neoplasms, Castration-Resistant. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

Metastatic castration-resistant prostate cancer (mCRPC) is a heterogeneous disease with varying survival outcomes. This study investigated whether baseline PSMA PET/CT parameters are associated with survival and treatment response.

Methods

Sixty mCRPC patients underwent [ 18 F]PSMA-1007 PET/CT before treatment with androgen receptor-targeted agents (ARTAs) or chemotherapy. Intensity-based parameters, volumetric parameters, metastatic sites and DmaxVox (distance between the two outermost voxels) from baseline PSMA PET/CT were collected, as well as age, Gleason score and laboratory parameters. Cox regression analysis evaluated their prognostic value for overall survival (OS). Additionally, a preliminary lesion-level analysis was done ( n = 241 lesions) with lesion location and twelve radiomic features selected from previous literature. Logistic regression evaluated their association with PSMA PET/CT-based lesion progression after 3–4 months of treatment.

Results

Total tumour volume (PSMA-TV) (HR = 1.41 per doubling [1.17–1.70]), total lesion uptake (TL-PSMA) (HR = 1.40 per doubling [1.16–1.69]) and DmaxVox (HR = 1.31 per 10 cm increase [1.07–1.62]) were prognostic for OS, each independent of baseline PSA level (HR = 0.82 per doubling [0.68–0.98]), haemoglobin level (HR = 0.68 per mmol/L increase [0.49–0.95]) and line of treatment. On lesion-level, location (prostate vs bone OR = 0.23 [0.06–0.83]) and SUV mean (OR = 1.72 per doubling [1.08–2.75]) were independent prognostic markers for lesion progression, morphological and texture-based radiomic features were not.

Conclusion

Baseline PSMA PET/CT scans have prognostic value in mCRPC patients and can potentially aid in treatment decision-making. DmaxVox can serve as a simpler alternative to PSMA-TV when automated segmentation software is not available. When combined with PSMA-TV, lower PSA levels indicated worse OS, which may be a marker of tumour dedifferentiation. Further research is needed to validate these models in larger patient cohorts. Key Points Question mCRPC is a highly heterogeneous disease, requiring good prognostic markers .

Findings

PSMA-TV was the best independent prognostic marker for OS; maximum distance between lesions (DmaxVox) can be used as a simpler alternative . Clinical relevance Baseline PSMA PET/CT parameters representing tumour burden were independently associated with OS in mCRPC patients, providing prognostic insights for clinical decision-making. Although PSMA-TV was the best prognostic marker, DmaxVox can serve as an easier to obtain alternative .

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Positron Emission Tomography Computed TomographyProstatic Neoplasms, Castration-ResistantHumansMaleAgedMiddle AgedPrognosisTreatment OutcomeOligopeptidesAged, 80 and overRadiopharmaceuticalsRetrospective StudiesNeoplasm MetastasisNiacinamide

Stichwörter der Autor:innen

PSMA-1007Positron-emission tomographyProstatic neoplasms, Castration-resistantSurvival

Substanzen

OligopeptidesPSMA-1007RadiopharmaceuticalsNiacinamide

Autor:innen und Institutionen

  • Biomedical Photonic Imaging Group, University of Twente, Enschede, The Netherlands. F.Kleiburg@lumc.nl.
  • Department of Radiology, Section of Nuclear Medicine, Leiden University Medical Center, Leiden, The Netherlands. F.Kleiburg@lumc.nl.
  • Biomedical Photonic Imaging Group, University of Twente, Enschede, The Netherlands.
  • Department of Radiology, Section of Nuclear Medicine, Leiden University Medical Center, Leiden, The Netherlands.
  • Department of Radiation Science & Technology, Delft University of Technology, Delft, The Netherlands.
  • Multi-Modality Medical Imaging, University of Twente, Enschede, The Netherlands.

Zitieren

APA

Kleiburg, F., de Geus-Oei, L. F., Spijkerman, R., Noortman, W. A., van Velden, F. H. P., Manohar, S., Smit, F., Toonen, F. A. J., Luelmo, S. A. C., van der Hulle, T., & Heijmen, L. (2025). Baseline PSMA PET/CT parameters predict overall survival and treatment response in metastatic castration-resistant prostate cancer patients. European Radiology, 35(7), 4223-4232. https://doi.org/10.1007/s00330-025-11360-3

Vancouver

Kleiburg F, de Geus-Oei LF, Spijkerman R, Noortman WA, van Velden FHP, Manohar S, et al. Baseline PSMA PET/CT parameters predict overall survival and treatment response in metastatic castration-resistant prostate cancer patients. European Radiology. 2025;35(7):4223-4232. doi:10.1007/s00330-025-11360-3

BibTeX
@article{Kleiburg2025,
  author = {Kleiburg, Fleur and de Geus-Oei, Lioe-Fee and Spijkerman, Romy and Noortman, Wyanne A and van Velden, Floris H P and Manohar, Srirang and Smit, Frits and Toonen, Frank A J and Luelmo, Saskia A C and van der Hulle, Tom and Heijmen, Linda},
  title = {Baseline PSMA PET/CT parameters predict overall survival and treatment response in metastatic castration-resistant prostate cancer patients},
  journal = {European Radiology},
  year = {2025},
  volume = {35},
  number = {7},
  pages = {4223--4232},
  doi = {10.1007/s00330-025-11360-3}
}
Kostenlos starten →